Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ICVX

Icosavax (ICVX) Stock Price, News & Analysis

Icosavax logo

About Icosavax Stock (NASDAQ:ICVX)

Advanced Chart

Key Stats

Today's Range
$15.31
$15.31
50-Day Range
$15.31
$15.45
52-Week Range
$4.75
$16.10
Volume
N/A
Average Volume
1.22 million shs
Market Capitalization
$766.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

ICVX Stock News Headlines

We recommended Palantir in 2021, now we're recommending this...
Simply put: All the grandiose claims you hear about AI will amount to nothing without one key investment. That's why I believe the biggest AI gains will NOT come from the "Next NVIDIA"... or some obscure AI startup you've never heard of. In fact, I'm convinced the biggest gains will come from one company that - at first glance - has nothing to do with AI at all. It's a Texas-based firm that provides the backbone for the entire $15.7 trillion AI industry.
Vaxcyte Inc Ordinary Shares 5VA
NervGen Pharma Corp Ordinary Shares NGEN
Icosavax: Tender Offer With Contingent Value Right
Icosavax CVR Seems Fairly Valued
See More Headlines

ICVX Stock Analysis - Frequently Asked Questions

Icosavax, Inc. (NASDAQ:ICVX) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.81. The firm had revenue of $1.83 million for the quarter, compared to the consensus estimate of $3.30 million.

Icosavax (ICVX) raised $150 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Icosavax investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/15/2021
Today
1/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ICVX
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

Net Income
$-91,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$580,000.00
Book Value
$5.47 per share

Miscellaneous

Free Float
34,767,000
Market Cap
$766.88 million
Optionable
Optionable
Beta
1.28
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:ICVX) was last updated on 1/31/2025 by MarketBeat.com Staff
From Our Partners